Biotech Essentials, the Influencers Review


Biotech Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts, enthusiasts and thought-leaders.

On Oct 14, 2020
@HealthcareLdr shared
Artificial Intelligence will Transform Healthcare Within our Lifetime https://t.co/dCgCk5q1nc @LinkedInEditors #Healthcare #ArtificialIntelligence #HealthTech #PatientEngagement #DigitalHealth https://t.co/77gzN5Xr6l
Open

Artificial Intelligence will Transform Healthcare Within our Lifetime

Artificial Intelligence will Transform Healthcare Within our Lifetime

In the decade ahead, in the 2020s, AI will surpass people and doctors in diagnosis and predicting medical outcomes. AI is promising to see patterns in images that will correlate with ...

On Oct 15, 2020
@BiotechSweden shared
SPACs Surge as Biotech Booms #BioTech via https://t.co/2sI0UxJbpn https://t.co/DVt8D4lCpx
Open

SPACs Surge as Biotech Booms

SPACs Surge as Biotech Booms

NetworkNewsWire Editorial Coverage: As the world has focused on the search for COVID vaccines and therapeutics, biotech IPOs have quietly gone bonkers. As a matter of fact, 2020 is on track ...

On Oct 16, 2020
@BIODeutschland shared
RT @sirionbiotechmu: We are proud to announce that @Mustang_Bio has licensed our #lentiviral #tranduction enhancer LentiBOOST™ for use in the development of MB-207, a lentiviral gene therapy to treat patients with #XSCID. https://t.co/7kj8Ot8zST #viralvectors #raredisease https://t.co/HHt9aOeYY6
Open

Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech

Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech

Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy

On Oct 15, 2020
@prometheusgreen shared
KENYA: Researchers not Kenya farm productivity stagnating, needs biotech innovation https://t.co/en1VzOgvKX
Open

Advancing adoption of genetically modified crops as food and feed in Africa: The case of Kenya

Advancing adoption of genetically modified crops as food and feed in Africa: The case of Kenya

Genetically modified organisms (GMOs) and Genetic Engineering (GE) technology has been around since mid 1990s. Numerous successful applications of genetically modified (GM) crops have been ...

On Oct 15, 2020
@GeneticLiteracy shared
The USDA’s self-determination options for GE crop developers might prevent the agency from assessing if new plants pose risks and require oversight. https://t.co/E2iY8P3roa @JaffeGregory
Open

Analysis: Problematic provisions in new USDA rule for GE plants

Analysis: Problematic provisions in new USDA rule for GE plants

Over the last three months, the United States Department of Agriculture (USDA) has published materials and conducted webinar presentations to provide

On Oct 16, 2020
@modestannedi shared
RT @prometheusgreen: Genetic engineering techniques could play an important role in ensuring the future of global food security https://t.co/h97axWlMtR genetic modification makes much larger pool of genetic variation available, enabling drought-resistance
Open

The quest to end world hunger

The quest to end world hunger

Genetic engineering techniques could play an important role in ensuring the future of global food security.

On Oct 19, 2020
@FierceBiotech shared
M&A activity still looks fairly lively in 2020 despite a somewhat subdued start as the industry adapted to the looming coronavirus pandemic. https://t.co/u7ZpDjIr71
Open

The top 10 takeover targets in biopharma

The top 10 takeover targets in biopharma

Most if not all large-cap pharma and biotech companies are still in need of business development as they work to rebalance their operations. Cancer, rare disease, and to a lesser extent ...

On Oct 20, 2020
@Labiotech_eu shared
Choosing the right #business model can be essential for a young #biotech company to succeed. #Strategy consultant Robert Thong gives us his expert insight on the advantages of each model and discusses in which situations each of them is most suitable. 🧠 https://t.co/S5w3jSI45b
Open

Everything You Need to Know About Biotech Business Models

Everything You Need to Know About Biotech Business Models

What's my business model? Who do I partner with? How do I scale up? These are typical strategic questions a young biotech will regularly face.

On Oct 19, 2020
@GENbio shared
Rentschler Biopharma and [email protected]_bio Ink Leap-In Transposase Licensing Deal. Read more: https://t.co/E860euZYTp #biopharma #bioprocessing https://t.co/FHJOVqy4rp
Open

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler plans to integrate the technology into its in-house process with what it calls a fast, cost-effective, and stable platform.

On Oct 15, 2020
@BentheFidler shared
RT @LifeSciVC: It’s Raining Biotech SPACs! But why? They aren't for everyone, but there are some real benefits of SPACs for both sponsors and merger targets. #SPAC #Biotech https://t.co/A1j5qPeDeW
Open

It’s Raining Biotech SPACs!

It’s Raining Biotech SPACs!

SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been ...

On Oct 16, 2020
@GENbio shared
[email protected] raises $30 M in Financing. The new funding will help take their manufacturing platform to the market that delivers solutions to address the clinical and commercial manufacturing needs of cell and #genetherapy developers. Learn more: https://t.co/3KDStJHa7A https://t.co/FryA7W3zq3
Open

Ori Biotech Raises $30 Million in Financing

Ori Biotech Raises $30 Million in Financing

 Funds will be used to advance innovation in cell and gene therapy manufacturing.

On Oct 17, 2020
@adamfeuerstein shared
RT @HankGreelyLSJU: I've got a fun piece in @statnews First Opinions on Oct-Dec 1980: 2 months that shaped biotech. https://t.co/oo5jhLy0wt Five big things happened in 59 days. Is it meaningful or coincidence? I don't know. Is it important? Probably not, but I think it's interesting. You might, too.
Open

The two months in 1980 that shaped the future of biotech

The two months in 1980 that shaped the future of biotech

Five events in a two-month span in 1980 propelled the nascent biotech industry and university biotech research into the future.

On Oct 14, 2020
@merckgroup shared
Proud to see our efforts to combat #NTD #schistosomiasis are acknowledged by @WSJ as they rank us no 1! The reporters state: "serving local communities—and burnishing [..] reputations as socially responsible businesses—pays off." https://t.co/MTEWqdYmD4
Open

Pharmaceutical, Biotech and Banking Companies Lead the Way in Social Responsibility

Pharmaceutical, Biotech and Banking Companies Lead the Way in Social Responsibility

Some surprising leaders sit atop the social-capital category in the WSJ’s top 100 sustainably managed companies

On Oct 16, 2020
@JonEntine shared
GM insect-resistant Bt cotton boosted India's crop yields? Activist study says no, but crop biotech experts say yes https://t.co/poGG8j8wzU
Open

GM insect-resistant Bt cotton boosted India’s crop yields? Activist study says no, but crop biotech experts say yes

GM insect-resistant Bt cotton boosted India’s crop yields? Activist study says no, but crop biotech experts say yes

Was the introduction of transgenic (GMO) cotton seeds to India in 2002 the beginning of the renaissance of the country's then struggling cotton industry?

On Oct 16, 2020
@keanbirch shared
RT @passimproject: The second part in our blog series Interdisciplinary Reflections on ‘Patents as Capital’ is out! Our guest this week is Susi Geiger, aka @complexmarkets from @ucddublin Geiger is PI for @ERC_Research consolidator project @MISFIRES_ERC https://t.co/p3Lkq9Crja #patents https://t.co/i2g7ny2QyE
Open

Interdisciplinary Reflections on ‘Patents as Capital’ with Susi Geiger

Interdisciplinary Reflections on ‘Patents as Capital’ with Susi Geiger

Together with the ERC research group that I’m leading, I am researching ‘concerned markets’, that is markets where multiple actors’ interests, values and concerns clash (Geiger et al. In ...

On Oct 19, 2020
@FierceBiotech shared
M&A activity still looks fairly lively in 2020 despite a somewhat subdued start as the industry adapted to the looming coronavirus pandemic. https://t.co/u7ZpDjIr71
Open

The top 10 takeover targets in biopharma

The top 10 takeover targets in biopharma

Most if not all large-cap pharma and biotech companies are still in need of business development as they work to rebalance their operations. Cancer, rare disease, and to a lesser extent ...

On Oct 13, 2020
@Biotechnology shared
Exploding Biopharma Industry Going the Distance for Specialized Talent https://t.co/DMuPa6CD7k https://t.co/9UcgzoN9fO
Open

Exploding Biopharma Industry Going the Distance for Specialized Talent

Exploding Biopharma Industry Going the Distance for Specialized Talent

The urgency of 2020 has shone a spotlight on the investment and advances in the U.S. biotech industry over the past decade – and overall, it is looking strong.

On Oct 15, 2020
@biospace shared
Biopharma Money on the Move: October 7-14 #biospace #lifesciences #biotechnology #pharmaceuticals #biopharma https://t.co/9x2rex1r6l
Open

Biopharma Money on the Move: October 7-14

Biopharma Money on the Move: October 7-14

Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.